Investor Alert: Revance Therapeutics Faces Class Action Lawsuit Over Alleged Securities Violations
Investor Alert: Revance Therapeutics Lawsuit
A recent announcement from Bronstein, Gewirtz & Grossman, LLC, a prominent law firm, has raised the alarm for investors in Revance Therapeutics, Inc. (NASDAQ: RVNC). The firm has informed investors about a class action lawsuit that seeks to recover damages for alleged violations of federal securities laws. This lawsuit pertains to those who purchased Revance securities between February 29, 2024, and December 6, 2024.
Class Action Overview
The lawsuit aims to represent all individuals and entities that experienced significant financial losses during the specified period. The firm is urging affected investors to act quickly by visiting their site at bgandg.com/RVNC to learn more and join the legal action.
The lawsuit centers around claims that Revance's officers made materially false and misleading statements regarding the company’s business practices and financial outlook. Specifically, the complaint alleges four key points:
1. Revance was allegedly in breach of their Distribution Agreement, potentially leading to legal and financial repercussions.
2. The company faced a heightened risk of litigation due to the breach, threatening both its monetary assets and reputation.
3. This breach increased the likelihood of delays or changes to a proposed Tender Offer, significantly impacting investor decisions.
4. As a result of these circumstances, the public statements released by Revance during this time were misleading and untruthful.
Next Steps for Investors
With the class action already underway, investors who believe they are eligible must act promptly. Those who wish to view the detailed complaint can again visit bgandg.com/RVNC or reach out directly to Peretz Bronstein or Nathan Miller at Bronstein, Gewirtz & Grossman by calling 332-239-2660.
It's important to note that investors impacted by these issues have until March 4, 2025, to petition for lead plaintiff status in the lawsuit. However, it is worth mentioning that being a lead plaintiff is not a precondition for participating in any recovery from the lawsuit.
No Upfront Costs
Investors should feel reassured that they will not incur any costs upfront when joining this class action. Bronstein, Gewirtz & Grossman operates on a contingency fee basis, meaning they will only receive compensation for legal fees and expenses if the lawsuit results in a financial recovery for the investors.
With their reputation firmly established as a leading firm in representing investors concerning securities fraud, Bronstein, Gewirtz & Grossman has successfully recovered hundreds of millions for their clients across various cases. Investors are encouraged to stay updated through their social media channels, including LinkedIn, X (formerly Twitter), Facebook, and Instagram.
As always, investors should remain vigilant and informed, especially when potential legal actions may impact their investments.
Contact information for Bronstein, Gewirtz & Grossman is as follows:
Phone: 332-239-2660
Email: [email protected]
This legal update is provided as a public service announcement by Bronstein, Gewirtz & Grossman, LLC. Remember that past recoveries do not necessarily guarantee future results.*
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.